GlassScriptPhysician profile
Andrew M Cogan
NPI 1346280591
$5,546.48
in general payments reported to CMS, 2019-2025
28 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $93.99 · 2021: $434 · 2022: $642 · 2023: $1,411 · 2024: $1,301 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,128.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,320.85 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $862.13 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $703.00 | 2019-2025 | |
| Lilly USA, LLC | $428.98 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Exact Sciences Corporation | $427.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $359.12 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $291.79 | 2023-2025 | Repatha, Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $148.78 | 2019-2023 | Livalo, Seglentis |
| Otsuka America Pharmaceutical, INC. | $129.30 | 2024-2025 | Rexulti |
| Abbott Laboratories | $126.08 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Glaxosmithkline, LLC. | $112.16 | 2022-2025 | Shingrix, Bexsero, Trelegy Ellipta |
| Ibsa Pharma INC. | $82.48 | 2020-2022 | |
| Optinose US, INC. | $61.72 | 2023 | |
| Janssen Pharmaceuticals, INC | $49.32 | 2021-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $48.29 | 2023-2024 | Quviviq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $46.70 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $44.30 | 2022 | |
| Daiichi Sankyo INC. | $43.27 | 2019-2020 | |
| Amarin Pharma, INC. | $41.81 | 2019-2022 | |
| Horizon Therapeutics Plc | $38.87 | 2022 | |
| Lundbeck LLC | $36.22 | 2024-2025 | Rexulti |
| Sanofi Pasteur INC. | $29.97 | 2020-2021 | |
| Boston Scientific Corporation | $26.56 | 2025 | General - Pain Management |
| Sanofi-Aventis U.S. LLC | $22.31 | 2025 | |
| Inspire Medical Systems, INC. | $17.53 | 2024 | Inspire |
| Vertex Pharmaceuticals Incorporated | $16.81 | 2025 | |
| Organon LLC | $16.03 | 2025 | Vtama |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.69 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.